|
|
|
| Clinical efficacy of Mannatide combined with Mesalazine in the treatment of ulcerative colitis |
| WANG Limei1 XIANG Yi2 WU Ying1 LIANG Cong1 BAI Junfang1 |
1.Department of Gastroenterology, Shaanxi Second Provincial People′s Hospital, Shaanxi Province, Xi′an 710005, China;
2.Department of Gastroenterology, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 710065, China |
|
|
|
Abstract Objective To explore the clinical efficacy of Mannatide combined with Mesalazine in the treatment of patients with ulcerative colitis. Methods A total of 106 patients with ulcerative colitis admitted to Shaanxi Second Provincial People′s Hospital and the Second Affiliated Hospital of Shaanxi University of Chinese Medicine from August 2014 to December 2017 were collected as observation objects, they were divided into observation group and control group according to the random number table method, with 53 cases in each group. The control group was given Mesalazine alone, while the observation group was given Mannatide combined with Mesalazine. The clinical effect and adverse reactions of the two groups were recorded. The peripheral blood immune indexes CD3+, CD4+, CD4+/CD8+, NK cells were detected by flow cytometry. The serum levels of matrix metalloproteinase (MMP) -1, MMP-2, MMP-9 were determined by enzyme-linked immunosorbent assay (ELISA). Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P < 0.05). The CD3+, CD4+, CD4+/CD8+, NK cells levels in two groups after treatment were significantly higher than those before treatment, which in the observation group were higher than those in control group, the differences were statistically significant (P < 0.05). The MMP-1, MMP-2, MMP-9 levels in two groups after treatment were significantly lower than those before treatment, which in the observation group were lower than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Mannatide combined with Mesalazine in the treatment of ulcerative colitis can improve clinical efficacy, immune functions and body repair ability, and it doesn′t increase the incidence of adverse reactions, it′s safe and reliable.
|
|
|
|
|
|
[1] Ninomiya K，Hisabe T，Okado Y，et al. Comparison of Small Bowel Lesions Using Capsule Endoscopy in Ulcerative Colitis and Crohn′s Disease：A Single-Center Retrospective Analysis [J]. Digestion，2018，98（2）：119-126.
[2] Van de Vondel S，Baert F，Reenaers C，et al. Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis：a Real-World Belgian Cohort Study [J]. Inflamm Bowel Dis，2018，24（5）：1099-1105.
[3] 李军祥，陈誩.溃疡性结肠炎中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2018，26（2）：105-111，120.
[4] 王赛，周国华.氨基水杨酸类联合微生态制剂对溃疡性结肠炎的维持治疗进展[J].实用药物与临床，2015，18（4）：463-466.
[5] 何元清，何子彬，张晗，等.美沙拉嗪联合康复新液保留灌肠治疗活动期溃疡性结肠炎的临床观察[J].中国药房，2017，28（29）：4133-4136.
[6] 刘鹏林，赵刚，张立泽，等.甘露聚糖肽注射液干预治疗溃疡性结肠炎的前瞻性、随机、开放性对照临床研究[J].中国医药导刊，2012，14（4）：637-638，609.
[7] 安丰田，牟相成，朱文静.甘露聚糖肽合并化/放疗治疗恶性肿瘤的临床研究[J].药物生物技术，2017，24（3）：236-238.
[8] 中华医学会消化病学分会炎症性肠病协作组，欧阳钦，胡品津，等.对我国炎症性肠病诊断治疗规范的共识意见（2007年，济南）[J].中华消化杂志，2007，27（8）：545-550.
[9] 曾晓梅，李青松，张曦文，等.美沙拉嗪联合甘露聚糖肽注射液治疗溃疡性结肠炎的疗效及对血浆基质金属蛋白酶水平的影响[J].广西医科大学学报，2018，35（1）：57-60.
[10] Kawalec P，Stawowczyk E. Relationship between physician-based assessment of disease activity，quality of life，and costs of ulcerative colitis in Poland [J]. Prz Gastroenterol，2018，13（1）：61-68.
[11] 何晓瑞.溃疡性结肠炎的发病机制和药物治疗的研究进展[J].中国当代医药，2018，25（7）：25-27.
[12] 陈璐，周中银.溃疡性结肠炎发病机制的研究进展[J].疑难病杂志，2016，15（6）：650-654.
[13] Holleran G，Scaldaferri F，Ianiro G，et al. Fecal microbiota transplantation for the treatment of patients with ulcerative colitis and other gastrointestinal conditions beyond Clostridium difficile infection：an update [J]. Drugs Today（Barc），2018，54（2）：123-136.
[14] 阮水良，沈海燕，陆其明，等.2000～2014年我院炎症性肠病发病趋势及临床特征[J].中国医药导报，2016，13（22）：40-43.
[15] Holubar SD. Prevention，Diagnosis，and Treatment of Complications of the IPAA for Ulcerative Colitis [J]. Dis Colon Rectum，2018，61（5）：532-536.
[16] 朱颖玲，唐晓华，吴红铃.中西医结合疗法治疗溃疡性结肠炎的疗效及对凝血功能、炎性因子水平的影响分析[J].中国医药科学，2016，6（23）：82-86.
[17] Schaffler H，Huth A，Lamprecht G，et al. Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A [J]. Case Rep Gastroenterol，2017，11（3）：774-779.
[18] 许国华，张印，夏伦文，等.枯草杆菌二联活菌肠溶胶囊联合美沙拉嗪对轻、中度溃疡性结肠炎的疗效观察[J].中国医学创新，2017，14（31）：99-102.
[19] Chen L，Gao Y，Zhang Z，et al. Umbilical cord blood mononuclear cell therapy induces clinical remission of steroid-dependent or-resistant ulcerative colitis patients [J]. Oncotarget，2018，9（19）：15027-15035.
[20] 徐晓红.舒肝解郁胶囊联合美沙拉秦治疗溃疡性结肠炎的临床效果[J].中国医药导报，2018，15（16）：134-137，141.
[21] 张瑜鸿，苗新普.溃疡性结肠炎并发巨细胞病毒感染的临床特征及危险因素[J].实用预防医学，2018，25（3）：338-341.
[22] 周继旺，吴建业，陈军贤.序贯应用中药辅助治疗激素依赖性溃疡性结肠炎的临床分析[J].中国现代医生，2016，54（31）：122-125.
[23] 程华，李雪梅，杨爱萍，等.美沙拉嗪治疗溃疡性结肠炎的临床疗效及对ESR、PLT、D-二聚体影响的多中心研究[J].中国生化药物杂志，2014，34（9）：134-136，139.
[24] 王明蕾.美沙拉嗪联合双岐杆菌三联活菌治疗溃疡性结肠炎的疗效及对炎症因子水平的影响[J].中国医药科学，2017，7（18）：43-45，126.
[25] 龚隆辉，赖锦茂，吴坤凤，等.美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的效果比较[J].中国当代医药，2018， 25（13）：154-156.
[26] 高海瑞，赵刚，迟玉花，等.甘露聚糖肽对溃疡性结肠炎病人TLR-2和TLR-4表达影响[J].青岛大学医学院学报，2015，51（3）：290-292.
[27] 徐康，童诚，崔俊丽.中药灌肠联合美沙拉嗪口服治疗溃疡性结肠炎临床观察[J].中国临床研究，2016，29（7）： 959-961.
[28] 张莉，顾清，代小松，等.美沙拉嗪联合布拉氏酵母菌散治疗溃疡性结肠炎的疗效及对炎症因子的影响[J].西部医学，2018，30（7）：1002-1004，1009.
[29] 赵静，易静.美沙拉嗪联合双歧杆菌三联活菌胶囊治疗溃疡性结肠炎及对患者血清hs-CRP、ESR、PLT、D-二聚体的影响[J].中国医学创新，2017，14（35）：114-117.
[30] 吴崑，严红丽，穆敬平.MMP-2、MMP-9与溃疡性结肠炎患者肠黏膜通透性的相关性研究[J].临床与病理杂志，2016，36（4）：384-388.
[31] 马艳.美沙拉嗪对溃疡性结肠炎患者肠道黏膜屏障功能和免疫功能的系统评价[J].中国现代医生，2018，56（9）：35-38.
[32] 薛永举，梅俏，丁浩，等.溃疡性结肠炎患者外周血中MMP-2、MMP-9与肠黏膜通透性关系的临床研究[J].安徽医科大学学报，2014，49（4）：495-498.
[33] 蒋继周，金一，郑舒丹，等.外周血中MMP-2、MMP-9与溃疡性结肠炎患者肠黏膜通透性的相关性分析[J].胃肠病学和肝病学杂志，2015，24（11）：1387-1389. |
|
|
|
